Tuying Yong
Overview
Explore the profile of Tuying Yong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
803
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhang X, Wei Z, Yong T, Li S, Bie N, Li J, et al.
Nat Commun
. 2023 Sep;
14(1):5653.
PMID: 37704614
The durable response rate to immune checkpoint blockade such as anti-programmed cell death-1 (PD-1) antibody remains relatively low in hepatocellular carcinoma (HCC), mainly depending on an immunosuppressive microenvironment with limited...
12.
Zhang L, Wang S, Wu G, Yue H, Dong R, Zhang S, et al.
Cell Death Dis
. 2023 May;
14(5):303.
PMID: 37142578
Despite past extensive studies, the pathoetiologies underlying tumor metastasis remain poorly understood, which renders its treatment largely unsuccessful. The methyl-CpG-binding domain 2 (MBD2), a "reader" to interpret DNA methylome-encoded information,...
13.
Han S, Xue L, Wei Y, Yong T, Jia W, Qi Y, et al.
Adv Sci (Weinh)
. 2023 Apr;
10(17):e2207080.
PMID: 37096833
Bone is the second leading metastatic site for hepatocellular carcinoma (HCC). Patients with HCC and bone metastasis suffer poor quality of life and reduced survival time. Extracellular vesicles (EVs) are...
14.
Bie N, Yong T, Wei Z, Gan L, Yang X
Adv Drug Deliv Rev
. 2022 Jul;
188:114450.
PMID: 35841955
Extracellular vesicles (EVs), including microparticles and exosomes, have emerged as potential tools for tumor targeting delivery during the past years. Recently, mass of strategies are applied to assist EVs to...
15.
Yong T, Wei Z, Gan L, Yang X
Adv Mater
. 2022 Jun;
34(52):e2201054.
PMID: 35726204
Although immunotherapy harnessing activity of the immune system against tumors has made great progress, the treatment efficacy remains limited in most cancers. Current anticancer immunotherapy is primarily based on T-cell-mediated...
16.
Li X, Yong T, Wei Z, Bie N, Zhang X, Zhan G, et al.
Nat Commun
. 2022 May;
13(1):2794.
PMID: 35589680
Insufficient tumor accumulation and distribution of photosensitizers as well as low antitumor immunity severely restrict the therapeutic efficacy of photothermal therapy (PTT). Cancer-associated fibroblasts (CAFs) play a key role in...
17.
Li J, Li J, Yao Y, Yong T, Bie N, Wei Z, et al.
Theranostics
. 2022 May;
12(7):3503-3517.
PMID: 35547751
The perioperative trauma-related platelet recruitment and activation severely affect tumor recurrence and metastasis. Therefore, efficiently killing residual tumor cells and simultaneously inhibiting platelet activation to block platelet-cancer cell interaction might...
18.
Liang Q, Bie N, Yong T, Tang K, Shi X, Wei Z, et al.
Nat Biomed Eng
. 2021 Feb;
5(5):481.
PMID: 33558736
No abstract available.
19.
Wei Z, Zhang X, Yong T, Bie N, Zhan G, Li X, et al.
Nat Commun
. 2021 Jan;
12(1):440.
PMID: 33469052
The main challenges for programmed cell death 1(PD-1)/PD-1 ligand (PD-L1) checkpoint blockade lie in a lack of sufficient T cell infiltration, tumor immunosuppressive microenvironment, and the inadequate tumor accumulation and...
20.
Xu Q, Zhan G, Zhang Z, Yong T, Yang X, Gan L
Theranostics
. 2021 Jan;
11(4):1937-1952.
PMID: 33408790
Development of efficient therapeutic strategy to incorporate ultrasound (US)-triggered sonodynamic therapy (SDT) and ferroptosis is highly promising in cancer therapy. However, the SDT efficacy is severely limited by the hypoxia...